PrivatePulse·Companies·Helsing vs Vannevar Labs

Helsing vs Vannevar Labs: employee equity compared

Secondary market prices, valuation trajectory, equity structure, and liquidity outlook for employees choosing between Helsing and Vannevar Labs.

Secondary market data updated monthly · Sources: Hiive, Forge
↑ Higher secondary premium

Helsing

Defense · Munich, Germany · Founded 2021

European AI defence company developing software-defined sensor fusion, threat recognition, and autonomous targeting systems for NATO allies.

Last primary round$5.4B · Series C (2024-06)
Secondary market$5.6B (+4% vs primary)
Annual revenue$0.1B ARR · +150% YoY (very fast)
Headcount~500
Equity typeRSU
Illiquidity discount~30%
Last round leadGeneral Catalyst
Liquidity outlook

No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.

Key equity angle

Government-contract stability; RSU (no exercise cost); longer liquidity timeline vs consumer tech

Vannevar Labs

Defense · United States · Founded 2019

AI-native defence intelligence platform processing open-source, commercial, and classified data for the DoD and IC.

Last primary round$1.2B · Series B (2024-05)
Secondary market$1.2B (+0% vs primary)
Annual revenue$0.1B ARR · +80% YoY (fast)
Headcount~250
Equity typeISO/NSO
Strike price range$7–$14 (depends on cohort)
Illiquidity discount~25%
Last round leadBedrock Capital
Liquidity outlook

Early-stage — IPO 4–6+ years away. High-risk, high-upside equity. Liquidity most likely via acquisition or late-stage tender.

Key equity angle

Government-contract stability; ISO/NSO options; longer liquidity timeline vs consumer tech

Key differences for employees

Equity structure

Helsing grants RSU — no exercise cost. Your equity vests and converts to cash or shares automatically at a liquidity event. Vannevar Labs grants ISO/NSO with strike prices from $7–$14.

Secondary market premium

The secondary market is pricing Helsing at a +4% premium over its last primary round ($5.4B$5.6B). Vannevar Labs trades at +0% over its last round ($1.2B$1.2B). A higher secondary premium signals stronger investor demand and potentially better near-term liquidity for employees looking to sell.

Revenue and growth

Helsing runs at $0.1B ARR, growing +150% YoY (very fast). Vannevar Labs runs at $0.1B ARR, growing +80% YoY (fast). Revenue growth rate matters for equity because it drives the peer-multiple valuation — the method most correlated with exit multiples.

Liquidity timeline

Helsing: No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.

Vannevar Labs: Early-stage — IPO 4–6+ years away. High-risk, high-upside equity. Liquidity most likely via acquisition or late-stage tender.

Calculate your specific grant

Enter your actual shares, equity type, and strike price. PrivatePulse calculates your personal equity value at both companies using 4 independent methods.

Frequently asked questions

Is Helsing or Vannevar Labs a better company to work at for equity?
There's no universal answer — it depends on your risk profile, time horizon, and specific grant terms. Helsing at $5.4B and Vannevar Labs at $1.2B offer very different risk/reward profiles. Use the calculator above to model your exact grant at each company.
How do I know if my Helsing or Vannevar Labs equity is fairly priced?
Compare your grant's implied per-share value against the secondary market price. If investors are paying a premium on Hiive or Forge over the last primary round, that's a signal of strong demand. PrivatePulse shows you the gap between your 409A and what the secondary market says.
Can I sell my Helsing or Vannevar Labs shares on the secondary market?
Secondary market transactions (Hiive, Forge, Caplight) require accredited investor status and your company's consent — most private companies have right-of-first-refusal (ROFR) provisions. Tender offers, when available, are typically the most accessible path to partial liquidity for employees.

More equity comparisons